NCT01835067View on ClinicalTrials.gov

Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

November 30, 2019

Study Completion Date

December 31, 2019

Conditions
Exudative Macular DegenerationRetinal Hemorrhage
Interventions
DRUG

Ranibizumab

Single intravitreal injection of 500 micrograms ranibizumab in 0.05mls

DRUG

C3F8 Gas

Single intravitreal injection of 0.3 mls C3F8

DRUG

tPA

Single intravitreal injection of 50 micrograms tPA in 0.05 mls

Trial Locations (5)

ME16 9QQ

Maidstone Hospital, Maidstone

SR2 9HP

Sunderland Eye Infimary, Sunderland

HU3 2JZ

Hull & East Yorkshire Hospital NHS Trust, Hull

SE5 9RS

King's College Hospital NHS Foundation Trust, London

SS0 0RY

Southend University Hospital NHS Foundation Trust, Southend

All Listed Sponsors
lead

King's College Hospital NHS Trust

OTHER

NCT01835067 - Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD | Biotech Hunter | Biotech Hunter